{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:28:58Z","timestamp":1790378938376,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.04.004","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T16:17:46Z","timestamp":1462033066000},"page":"3412-3419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero\u00ae to reduce meningococcal group B disease in Germany"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-9733","authenticated-orcid":false,"given":"Hannah","family":"Christensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ultsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-7188","authenticated-orcid":false,"given":"Ole","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Hellenbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2016.04.004_bib0190","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0195","series-title":"Surveillance of invasive bacterial diseases in Europe, 2012","author":"Ciaravino","year":"2015"},{"issue":"9","key":"10.1016\/j.vaccine.2016.04.004_bib0200","first-page":"E060907.4","article-title":"Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany","volume":"11","author":"Wiese-Posselt","year":"2006","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.004_bib0205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jinf.2012.09.008","article-title":"Epidemiology of invasive meningococcal disease in Germany: 2002\u20132010, and impact of vaccination with meningococcal C conjugate vaccine","volume":"66","author":"Hellenbrand","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0210","first-page":"327","article-title":"Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut\/Stand: August 2015","volume":"34","year":"2015","journal-title":"Epidemiologisches Bulletin"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.004_bib0215","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0220","first-page":"394","article-title":"Wissenschaftliche begr\u00fcndung. Aktualisierung der meningokokken-impfempfehlung: anwendung des meningokokken-B-impfstoffs bei personen mit erh\u00f6htem risiko f\u00fcr meningokokken-erkrankungen","volume":"37","author":"Robert Koch Institute","year":"2015","journal-title":"Epidemiol Bull"},{"issue":"23","key":"10.1016\/j.vaccine.2016.04.004_bib0225","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2016.04.004_bib0230","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/14760584.2013.814862","article-title":"A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?","volume":"12","author":"Martin","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.004_bib0235","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1017\/S0950268805005339","article-title":"The natural history of meningococcal carriage and disease","volume":"134","author":"Trotter","year":"2006","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.004_bib0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1574-6976.2006.00052.x","article-title":"Lessons from meningococcal carriage studies","volume":"31","author":"Caugant","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2016.04.004_bib0245","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1086\/428590","article-title":"Genetic analysis of meningococci carried by children and young adults","volume":"191","author":"Claus","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2016.04.004_bib0250","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive Meningococcal Serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.004_bib0255","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/520303","article-title":"Complications and sequelae of meningococcal disease in Quebec: Canada, 1990\u20131994","volume":"26","author":"Erickson","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2016.04.004_bib0260","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1093\/cid\/cir500","article-title":"Comparative long-term adverse effects elicited by invasive Group B and C meningococcal infections","volume":"53","author":"Gottfredsson","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2016.04.004_bib0265","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/340050","article-title":"Influence of serogroup on the presentation: course, and outcome of invasive Meningococcal Disease in children in the Republic of Ireland, 1995\u20132000","volume":"34","author":"Healy","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2016.04.004_bib0270","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1017\/S0950268809002428","article-title":"Morbidity: mortality and spatial distribution of meningococcal disease, 1974\u20132007","volume":"137","author":"Howitz","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0275","doi-asserted-by":"crossref","DOI":"10.1002\/hec.3259","article-title":"Measuring health spillovers for economic evaluation: a case study in meningitis","author":"Al-Janabi","year":"2015","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0280","series-title":"International Pathogenic Neisseria Conference","article-title":"Meningococcal antigen typing system (MATS) based coverage for Bexsero on invasive MenB strains isolated from infants aged less than one year in Germany 2007\u20132013","author":"Claus","year":"2014"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0285","series-title":"Preisindex f\u00fcr Verbrauchs- und Gebrauchsg\u00fcter","author":"Destatis Statistisches Bundesamt","year":"2015"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0290","series-title":"Allgemeine Methoden. Version 4.2 vom 22.04.2015","author":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen","year":"2015"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2334-12-202","article-title":"Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010","volume":"12","author":"Dang","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.004_bib0300","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1542\/peds.2007-0167","article-title":"Childhood influenza: number needed to vaccinate to prevent 1 hospitalization or outpatient visit","volume":"120","author":"Lewis","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0305","series-title":"Empfehlung und wissenschaftliche Begr\u00fcndung der Empfehlung zur Rotavirus-Standardimpfung von S\u00e4uglingen","first-page":"35","author":"Robert Koch Institute","year":"2013"},{"issue":"9960","key":"10.1016\/j.vaccine.2016.04.004_bib0310","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.004_bib0315","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.004_bib0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4161\/hv.26986","article-title":"Vaccination coverage among children in Germany estimated by analysis of health insurance claims data","volume":"10","author":"Rieck","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0325","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"Br Med J"},{"issue":"42","key":"10.1016\/j.vaccine.2016.04.004_bib0330","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario: Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2016.04.004_bib0335","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0340","series-title":"Analyse co\u00fbt\/efficacit\u00e9 de la vaccination par le vaccin Bexsero\u00ae contre les infections invasives \u00e0 m\u00e9ningocoque de s\u00e9rogroupe B (IIM B)","author":"Lecocq","year":"2014"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0345","series-title":"Modelling the potential impact of Bexsero introduction in Belgium","author":"Hanquet","year":"2014"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.004_bib0350","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup b meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0355","article-title":"Modelled evaluation of multi-component meningococcal vaccine (Bexsero\u00ae) for the prevention of invasive meningococcal disease in infants and adolescents in the UK","author":"Huels","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0360","series-title":"Vaccination contre les infections invasives \u00e0 m\u00e9ningocoque B Place du vaccin Bexsero\u00ae","author":"Le Haut Conseil de la sant\u00e9 publique","year":"2013"},{"key":"10.1016\/j.vaccine.2016.04.004_bib0365","year":"2013"},{"issue":"48","key":"10.1016\/j.vaccine.2016.04.004_bib0370","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1016\/j.vaccine.2014.09.040","article-title":"Survey of pediatricians in Germany reveals important challenges for possible implementation of meningococcal B vaccination","volume":"32","author":"Takla","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T12:51:34Z","timestamp":1536756694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16301244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":37,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16301244"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero\u00ae to reduce meningococcal group B disease in Germany","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}